Pie Medical Imaging releases new version of CAAS QCA-Research

Pie Medical Imaging BV of Maastricht, the Netherlands, introduced a new version of its CAAS Quantitative Coronary Analysis for Research software (CAAS QCA-R), QCA for Research 2.0, at the American College of Cardiology meeting, March 6 - 9, in Orlando, Fla.
   
The new version improves the method to evaluate the effectiveness of drug eluting stents (DES) by allowing users to analyze the proximal, distal and stented segment very quickly, the company said. Additional improvements include optimized multiple subsegments analysis, expanded subsegmental data analysis, more overall results and floating license possibility.    
   
Pie Medical Imaging CAAS software offers automatic contour detection of the coronary arteries and analysis of its dimensions. After calibration and contour detection of the artery, the analysis results are presented instantly. In addition to computer defined obstruction analysis, CAAS QCA-R offers user reference analysis, subsegments analysis, brachytherapy analysis and fast drug eluting stents (DES) analysis.
   
Results can be saved in DICOM, MS-Access and/or MS-Excel file formats, Pie Medical Imaging said.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.